Related Experiment Video
Updated: Aug 15, 2026

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
Published on: January 7, 2019
Human immunodeficiency virus type 1 phenotypes in children with advanced disease treated with long-term zalcitabine
R M Viani1, I L Smith, S A Spector
1Department of Pediatrics, University of California at San Diego, La Jolla 92093-0672, USA.
Insights
Zalcitabine monotherapy in HIV-1 infected children showed a low incidence of drug resistance. Some patients experienced a switch from syncytium-inducing (SI) to non-SI (NSI) HIV-1 phenotypes during treatment.
Area of Science:
- Virology
- Pediatric Infectious Diseases
- Antiretroviral Therapy
Background:
- Human immunodeficiency virus type 1 (HIV-1) infection in children requires effective antiretroviral strategies.
- Zidovudine-experienced children were enrolled in a trial evaluating zalcitabine monotherapy.
- Understanding viral phenotype and resistance is crucial for treatment selection.
Purpose of the Study:
- To assess the syncytium-inducing (SI) phenotype and zalcitabine resistance in HIV-1 isolates from children.
- To evaluate changes in viral phenotype during zalcitabine monotherapy.
- To inform combination antiretroviral drug selection.
Main Methods:
- Prospective trial of zalcitabine (dideoxycytidine) monotherapy in 38 HIV-1 infected children.
- Analysis of baseline and posttreatment HIV-1 isolates for SI/NSI phenotype.
- In vitro drug susceptibility assays to determine zalcitabine resistance.
Main Results:
- Twenty baseline isolates were SI, and 18 were NSI.
- Phenotype stability was observed in most patients (>44 weeks of treatment).
- Low incidence of zalcitabine resistance (3%) and some SI-to-NSI phenotype reversion (20%) were noted.
Conclusions:
- Zalcitabine monotherapy demonstrates a low rate of resistance development in this pediatric cohort.
- A significant proportion of patients showed a switch from SI to NSI HIV-1 phenotype.
- These findings are valuable for guiding future antiretroviral treatment choices in children.
Abstract:
Baseline and posttreatment human immunodeficiency virus type 1 (HIV-1) isolates from 38 symptomatic, zidovudine-experienced HIV-1-infected children enrolled in a prospective trial of zalcitabine (dideoxycytidine) monotherapy (Pediatric AIDS Clinical Trials Group 138) were studied for the presence of syncytium-inducing (SI) phenotype and zalcitabine resistance. Twenty of the isolates were SI and 18 were non-SI (NSI) at baseline. After >44 weeks of zalcitabine treatment, the SI and NSI phenotypes were maintained in 16 and 17 patients, respectively. One patient had an NSI-to-SI phenotypic switch, while SI-to-NSI reversion occurred in 4 children (20%). Isolates from 30 of these patients were analyzed by in vitro drug susceptibility assay: Mean IC50 values were 0.14 microM at baseline and 0.18 microM following zalcitabine treatment. Only 1 child (3%) developed zalcitabine resistance. Knowledge of the low incidence of zalcitabine resistance and the switch from SI to NSI phenotype in some children may prove useful when selecting antiretroviral drugs to be used in combination.
Related Concept Videos
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Cytomegalovirus Disease
Cryptococcal Meningitis

